Results 131 to 140 of about 61,613 (221)

Response of small intestinal epithelial cells to irinotecan.

, 2013
(A) Significant decrease in the number of BrdU postive cells in the small intestinal crypts of irinotecan-treated mice. WT mice were injected with PBS (cont) or irinotecan (CPT) for 6 consecutive days and sacrificed on day 7. One hour prior to sacrifice,
Helen Piwnica-Worms (251639), Lynn S. White (357111), Sofia Origanti (357109), Gwanghee Lee (271155), Thaddeus S. Stappenbeck (357117), Jinwu Sun (357114)   +5 more
core   +1 more source

Machine Learning and Structural Analysis for Generation‐Wise Selection of Perylene Diimide Dendrimers Based on Topological Compatibility With Drug Molecules

ChemistryOpen, Volume 15, Issue 11, November 2026.
Machine learning and graph‐theoretic descriptors are integrated to evaluate topology‐based compatibility between perylene diimide‐core dendrimer generations and antiviral, antioxidant, and imaging agents. Standardized structural similarity reveals generation‐dependent compatibility patterns, while Gaussian process regression uncovers key structure ...
Zainab Bibi, Jabbar Ali, Sana Irshad, Muhammad Saad Ghafar, Yasir Ali, Yilun Shang   +5 more
wiley   +1 more source

Irinotecan-induced diarrhea:functional significance of the polymorphic ABCC2 transporter protein

, 2007
Interindividual pharmacokinetic variability of the anticancer agent irinotecan is high. Life-threatening diarrhea is observed in up to 25% of patients receiving irinotecan and has been related with irinotecan pharmacokinetics and UGT1A1 genotype status ...
McLeod, HL, de Jong, FA (Floris), Kroetz, DL, Verweij, Jaap, Friberg, Lena E.,, de Jong, F. A., Marsh, S, McLeod, H. L., Mathijssen, R. H., Kroetz, D. L., Verweij, J., Sparreboom, A., Scott-Horton, TJ, Sparreboom, A, Marsh, S., Mathijssen, RH; id_orcid, Friberg, LE, Scott-Horton, T. J.   +17 more
core   +1 more source

New Treatment Strategy and Future Research Direction for BRAF‐Mutated Cancer

Cancer Science, Volume 117, Issue 11, Page 2901-2909, November 2026.
Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Masanobu Takahashi, Sakura Hiraide Taniguchi, Yuya Yoshida   +2 more
wiley   +1 more source

Direct tumour–adipocyte contact / Stroma AReactive Invasion Front Area (TAC/SARIFA) predicts adverse outcome in colorectal cancer: a focused evidence synthesis and meta‐analysis

Histopathology, Volume 89, Issue 5, Page 835-848, November 2026.
TAC/SARIFA, defined by direct tumour–adipocyte contact at the invasion front, represents a reproducible, biologically meaningful H&E biomarker with consistent adverse prognostic associations in CRC. Aims Direct tumour‐adipocyte interaction at the invasion front, termed Stroma AReactive Invasion Front Areas (SARIFA), has recently emerged as a novel H&E ...
Nic G Reitsam, Bruno Märkl, Iris D Nagtegaal, Magali Svrcek   +3 more
wiley   +1 more source

Predictive Biomarkers in Metastatic Colorectal Cancer Patients Treated With Bevacizumab: A Turkish Oncology Group (TOG) Study

International Journal of Cancer, Volume 159, Issue 8, Page 2075-2083, 15 October 2026.
Bevacizumab added to systemic chemotherapy remains a cornerstone of metastatic colorectal cancer treatment, but its effectiveness is variable. Tumors can bypass the VEGF blockade by activating other pro‐angiogenic pathways, hampering the identification of predictive biomarkers.
Büsra Akay Hacan, Fatma Gizem Sonugür, Müge Öçal, Cansu Babahan, Samira Abgarmi, Ülkü Yalçıntaş Arslan, Mehmet Ali Şendur, Ahmet Demirkazık, Güngör Utkan, Hakan Akbulut   +9 more
wiley   +1 more source

Reactivation of hepatitis B after irinotecan

, 2004
Objective: To analyse the incidence of hepatitis B reactivation following treatment with irinotecan-based combined chemotherapy and the outcomes of patients with hepatitis B reactivation.
Kwok, CCH, Lui, LCY, Yau, CC, Wong, WM, Lai, CL, Au, GKH, Chan, RTT   +6 more
core  

Maritoclax Overcomes FBW7 Deficiency‐Driven Irinotecan Resistance in Colorectal Cancer by Targeting MCL1

Cancer Medicine
Introduction FBW7, a tumor suppressive E3 ubiquitin ligase frequently mutated in colorectal cancer (CRC), mediates chemotherapy resistance. While irinotecan (via its active metabolite SN38) is a first‐line TOP1 inhibitor for advanced CRC, the mechanistic
Qian Lin, Shuting Liu, Hongfei Jiang, Shasha Wang, Yixin Duan   +4 more
doaj   +1 more source

Real-world analysis of genotype-guided treatment for carriers of actionable DPYD and UGT1A1 variants. [PDF]

Pharmacogenomics J
Pasternak AL, Tackett W, Banerjee M, Paul S, Bertucci-Richter E, Zhou X, Sahai V, Hertz DL.   +7 more
europepmc   +1 more source

Long-Term Drug Screening Identifies PARP Inhibitors as Irinotecan Combination Partners in BRCA1/2-Wild-Type Pancreatic Ductal Adenocarcinoma. [PDF]

Pharmaceuticals (Basel)
Jang H, Jang H, Yun HY, Lee KY, Jang H.
europepmc   +1 more source